13F Holdings
中文EN

WHWK Whitehawk Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1422142 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-72.5%
TTM net income YoY67.7%
TTM EPS YoY86.0%
Revenue 3-yr CAGR-22.3%
Net income 3-yr CAGR—

Margins

Gross margin89.4%
Operating margin-1,601.1%
Net margin-288.3%
FCF margin-1,371.4%
EBITDA margin-1,600.0%

Returns

ROE-21.8%
ROA-18.6%
ROIC (approx.)-147.5%
Asset turnover0.06x

Leverage & solvency

Liabilities / assets9.6%
Debt / equity0.00x
Current ratio10.26x
Interest coverage—

Cash quality & payout

Operating cash flow / net income4.73x
Accruals ratio69.5%
Payout ratio—
Capex / revenue7.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$7.14M$25.98M$24.35M$15.22M$14.00M
Cost of revenue$760,000$3.02M$2.81M$1.33M$0
Gross profit$6.38M$22.96M$21.55M$13.88M$14.00M
R&D expense$90.96M$51.03M$48.93M$32.66M$19.67M
SG&A expense$29.82M$36.75M$44.55M$40.18M$18.51M
Operating income-$114.40M-$67.46M-$71.93M-$62.68M-$111.22M
Interest expense$0$154,000$231,000$230,000$665,000
Pretax income-$20.60M-$63.69M-$65.77M-$60.51M-$110.09M
Income tax$0$0$0$0$2,000
Net income-$20.60M-$63.69M-$65.77M-$60.51M-$110.09M
EBITDA-$114.32M-$67.27M-$71.76M-$62.52M-$111.11M
EPS (basic)-0.33-2.36-2.44-2.69-12.41
EPS (diluted)-0.33-2.36-2.44-2.69-12.41
Weighted avg. shares (diluted)61.89M27.03M26.92M22.51M8.92M
Banking
Provision for credit losses————$171,000
Balance sheet
Cash & equivalents$37.57M$28.67M$62.89M$39.02M$148.99M
Short-term investments$108.13M$18.57M$45.96M$133.54M$0
Receivables$0$5.90M$5.49M$1.86M$0
Inventory$0$5.31M$6.43M$1.86M$0
Current assets$149.01M$61.29M$124.59M$180.03M$151.27M
PP&E, net$3,000$6.85M$4.80M$508,000$57,000
Intangibles———$0$3.81M
Total assets$150.83M$70.32M$132.42M$184.24M$157.91M
Current liabilities$14.52M$17.07M$26.39M$18.84M$15.27M
Total liabilities$14.52M$17.84M$27.23M$25.86M$21.50M
Shareholders' equity$136.31M$52.48M$105.19M$158.38M$136.41M
Shares outstanding47.15M24.68M24.55M24.44M20.89M
Cash flow statement
Operating cash flow-$97.43M-$59.55M-$59.66M-$49.64M-$22.42M
Capital expenditure$552,000$1.65M$3.97M$444,000$46,000
Free cash flow-$97.98M-$61.20M-$63.63M-$50.08M-$22.47M
Investing cash flow$11.89M$25.20M$83.21M-$132.89M$25.15M
Financing cash flow$94.38M$130,000$326,000$72.62M$141.80M
Depreciation & amortization$79,000$193,000$169,000$159,000$105,000
Stock-based compensation$9.87M$10.84M$11.95M$9.64M$2.11M
Dividends paid———$0$4.41M

Free plan shows the latest 5 periods; Pro shows all 18 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.